Efficacy and safety of anti-androgens in the management of polycystic ovary syndrome: a systematic review and meta-analysis of randomised controlled trials

[1]  T. Piltonen,et al.  Combined oral contraceptive pill compared with no medical treatment in the management of polycystic ovary syndrome: A systematic review , 2023, Clinical endocrinology.

[2]  T. Grogan,et al.  Randomized clinical trial: effect of low-dose flutamide on abdominal adipogenic function in normal-weight women with polycystic ovary syndrome. , 2022, Fertility and sterility.

[3]  F. Villarroya,et al.  The relative deficit of GDF15 in adolescent girls with PCOS can be changed into an abundance that reduces liver fat , 2021, Scientific Reports.

[4]  T. Piltonen,et al.  Update on PCOS: Consequences, Challenges and Guiding Treatment. , 2020, The Journal of clinical endocrinology and metabolism.

[5]  A. López-Bermejo,et al.  Toward a Treatment Normalizing Ovulation Rate in Adolescent Girls With Polycystic Ovary Syndrome , 2020, Journal of the Endocrine Society.

[6]  T. Piltonen,et al.  Harmonising research outcomes for polycystic ovary syndrome: an international multi-stakeholder core outcome set. , 2020, Human reproduction.

[7]  A. López-Bermejo,et al.  Towards a circulating marker of hepato‐visceral fat excess: S100A4 in adolescent girls with polycystic ovary syndrome — Evidence from randomized clinical trials , 2019, Pediatric obesity.

[8]  F. Villarroya,et al.  Low-Dose Spironolactone-Pioglitazone-Metformin Normalizes Circulating Fetuin-A Concentrations in Adolescent Girls with Polycystic Ovary Syndrome , 2018, International journal of endocrinology.

[9]  P. Erwin,et al.  Treatment Options for Hirsutism: A Systematic Review and Network Meta-Analysis , 2018, The Journal of clinical endocrinology and metabolism.

[10]  F. Petraglia,et al.  Combined Oral Contraception and Bicalutamide in Polycystic Ovary Syndrome and Severe Hirsutism: A Double-Blind Randomized Controlled Trial , 2017, The Journal of clinical endocrinology and metabolism.

[11]  H. Escobar-Morreale,et al.  Combined oral contraceptives plus spironolactone compared with metformin in women with polycystic ovary syndrome: a one-year randomized clinical trial. , 2017, European journal of endocrinology.

[12]  H. Teede,et al.  Differential Effects on Haemostatic Markers by Metformin and the Contraceptive Pill: A Randomized Comparative Trial in PCOS , 2017, Thrombosis and Haemostasis.

[13]  Ó. Pozo,et al.  Normalizing Ovulation Rate by Preferential Reduction of Hepato-Visceral Fat in Adolescent Girls With Polycystic Ovary Syndrome. , 2017, The Journal of adolescent health : official publication of the Society for Adolescent Medicine.

[14]  Ulf Böckenholt,et al.  Single Paper Meta-Analysis: Benefits For Study Summary, Theory-Testing, and Replicability , 2017 .

[15]  E. Karabulut,et al.  The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. , 2016, Human reproduction.

[16]  R. Azziz,et al.  Androgen excess: Investigations and management. , 2016, Best practice & research. Clinical obstetrics & gynaecology.

[17]  R. An,et al.  Effects of metformin on pregnancy outcomes in women with polycystic ovary syndrome , 2016, Medicine.

[18]  D. Ehrmann,et al.  The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited. , 2016, Endocrine reviews.

[19]  F. Mehrabian,et al.  Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatin on the metabolic consequences of polycystic ovary syndrome , 2016, Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences.

[20]  K. Black,et al.  Choosing a combined oral contraceptive pill. , 2015, Australian prescriber.

[21]  Ali Bijani,et al.  Effect of Metformin and Flutamide on Anthropometric Indices and Laboratory Tests in Obese/Overweight PCOS Women under Hypocaloric Diet , 2014, Journal of reproduction & infertility.

[22]  Miriam Steinschneider,et al.  Role of the combination spironolactone-norgestimate-estrogen in Hirsute women with polycystic ovary syndrome. , 2014, The Journal of reproductive medicine.

[23]  S. Jafri,et al.  Bicalutamide-induced hepatotoxicity: A rare adverse effect , 2014, The American journal of case reports.

[24]  A. Amoah,et al.  Effect of hormonal contraceptives on lipid profile and the risk indices for cardiovascular disease in a Ghanaian community , 2014, International journal of women's health.

[25]  G. De Pergola,et al.  Intermittent low-dose finasteride administration is effective for treatment of hirsutism in adolescent girls: a pilot study. , 2014, Journal of pediatric and adolescent gynecology.

[26]  P. Guzzi,et al.  In PCOS patients the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism than metformin alone. , 2014, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[27]  M. Eijkemans,et al.  The effect of combined oral contraception on testosterone levels in healthy women: a systematic review and meta-analysis , 2013, Human reproduction update.

[28]  S. Nisar,et al.  Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a six-month, open-label randomized study. , 2013, The Journal of clinical endocrinology and metabolism.

[29]  Simone Rossi,et al.  Australian Medicines Handbook , 2012 .

[30]  R. Ferriani,et al.  The effects of 2 mg chlormadinone acetate/30 mcg ethinylestradiol, alone or combined with spironolactone, on cardiovascular risk markers in women with polycystic ovary syndrome. , 2012, Contraception.

[31]  G. Guyatt,et al.  GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. , 2011, Journal of clinical epidemiology.

[32]  A. Badawy,et al.  Treatment options for polycystic ovary syndrome , 2011, International journal of women's health.

[33]  H. Scher,et al.  Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. , 2009, The Lancet. Oncology.

[34]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement , 2009, BMJ : British Medical Journal.

[35]  R. Norman,et al.  The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. , 2009, Fertility and sterility.

[36]  O. Koulouri,et al.  A systematic review of commonly used medical treatments for hirsutism in women , 2008, Clinical endocrinology.

[37]  Susan Sam.  Obesity and Polycystic Ovary Syndrome. , 2007, Obesity management.

[38]  H. Teede,et al.  Effects of Medical Therapy on Insulin Resistance and the Cardiovascular System in Polycystic Ovary Syndrome , 2007 .

[39]  Antonio Maria Morselli-Labate,et al.  Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study. , 2006, The Journal of clinical endocrinology and metabolism.

[40]  N. Sattar,et al.  Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses. , 2005, The Journal of clinical endocrinology and metabolism.

[41]  G. De Pergola,et al.  Intermittent low-dose finasteride is as effective as daily administration for the treatment of hirsute women. , 2004, Fertility and sterility.

[42]  S. Dwivedi,et al.  Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: an open-labeled study. , 2004, The Journal of clinical endocrinology and metabolism.

[43]  F. de Zegher,et al.  Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity. , 2004, The Journal of clinical endocrinology and metabolism.

[44]  P. Eacho,et al.  Estrogen receptor-mediated repression of human hepatic lipase gene transcription. , 2002, Journal of lipid research.

[45]  P. Spritzer,et al.  Spironolactone as a single agent for long‐term therapy of hirsute patients , 2000, Clinical endocrinology.

[46]  L. Falsetti,et al.  Comparison of finasteride versus flutamide in the treatment of hirsutism. , 1999, European journal of endocrinology.

[47]  J. Ménard,et al.  Antiandrogenic effect of spirolactones: mechanism of action. , 1975, Endocrinology.

[48]  A. Goldman,et al.  INDUCED GENITAL ANOMALIES * , 1967, Annals of the New York Academy of Sciences.

[49]  H. Diri,et al.  COMPARISON OF FINASTERIDE, METFORMIN, AND FINASTERIDE PLUS METFORMIN IN PCOS. , 2017, Acta endocrinologica.

[50]  M. Mohammad,et al.  Polycystic Ovary Syndrome (PCOS), Diagnostic Criteria, and AMH , 2017, Asian Pacific journal of cancer prevention : APJCP.

[51]  K. Tilleman,et al.  Manual for ESHRE guideline development , 2017 .

[52]  H. Teede,et al.  Polycystic ovary syndrome , 2016, Nature Reviews Disease Primers.

[53]  L. Moran,et al.  Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis. , 2015, Human reproduction update.

[54]  E. Buckel,et al.  Acute and fulminant hepatitis induced by flutamide: case series report and review of the literature. , 2011, Annals of hepatology.

[55]  S. Sachdeva.  HIRSUTISM: EVALUATION AND TREATMENT , 2010, Indian journal of dermatology.

[56]  Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. , 2004, Fertility and sterility.

[57]  G. De Pergola,et al.  Comparison of Diane 35 and Diane 35 plus finasteride in the treatment of hirsutism. , 2000, Fertility and sterility.